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Historically, total pancreatectomy was reserved as a last resort for
patients in whom all other options for managing intractable pain
caused by chronic pancreatitis had been exhausted. Typically,
completion pancreatectomy was employed in patients in whom
either a drainage procedure or a pancreatic resection had failed.
Islet autotransplantation has made total pancreatectomy a more
attractive primary surgical option because it both preserves
endogenous insulin production and removes all of the chronica-
lly inflamed and fibrosed pancreatic parenchyma. Moreover,
although it does not necessarily prevent any future need for exog-
enous insulin, the diabetic state that results is less ‘brittle’.
Billings et al.1 reported that quality of life following total pan-
createctomy with longterm follow-up is decreased compared with
that in age- and gender-matched controls, and noted a 3% mor-
tality rate from hypoglycaemia. Islet autotransplantation helps to
avoid the dangerous problem of hypoglycaemia unawareness
experienced by many patients who undergo total pancreatectomy
without it. The durability of islet autotransplantation following
total pancreatectomy has been previously reported.2–4
In August’s issue, Morgan et al.5 presented 36 patients who
underwent total pancreatectomy and islet autotransplantation
over a 15-month period.Although follow-upwas limited, themain
thrust of the authorswas that themode of islet autotransplantation
has implications with regard to the overall cost of the procedure.
Three techniques have been used to infuse islets into the portal
circulation following the obligate delay (approximately 4 h) from
harvesting to the completion of islet processing: (i) maintaining
the patient under general anaesthesia, with the abdomen open,
until the processed islets are returned to the operating room (OR)
for infusion into the portal circulation; (ii) postoperative percu-
taneous transhepatic infusion utilizing interventional radiologic
techniques (the procedure used in the present report5), and (iii)
operative placement of a catheter in the portal circulation via a
colic vein or the recanalized umbilical vein, as reported by Ong
et al.,6 with autologous islet infusion conducted via the catheter in
a monitored setting (intensive care unit) postoperatively.
They report an estimated saving per patient of approximately
US$20 000 in decreased OR time, and an opportunity cost-
saving of US$12 871 represented by the additional surgeon pro-
ductivity engendered by more efficient use of the OR and surgeon
availability. The authors conclude that postoperative percutane-
ous transhepatic islet autotransplantation is safe and more cost-
effective than the more common procedure of maintaining the
patient under anaesthesia in the OR until the islets are available
for infusion.5 These conclusions are valid based upon the data
presented.
At our institution early in our experience with islet autotrans-
plantation, we elected to use postoperative percutaneous transhe-
patic infusion using interventional radiology expertise. However,
of late we have settled on an approach which we believe is safe,
effective and more cost-efficient than either intraoperative or per-
cutaneous transhepatic infusion. More recently, we have utilized
intraoperative catheter placement into the portal vein via either a
colic vein branch or the recanalized umbilical vein. This method of
securing themesocolon or the round ligament to the undersurface
of the abdominal wall and bringing the catheter out percutane-
ously allows the catheter to be removed from the low-pressure
portal venous system after islet infusion without the need for an
additional surgical procedure.
Total pancreatectomy and islet autotransplantation will be
offered increasingly to patients with chronic pancreatitis and
intractable pain in whom medical and interventional endoscopic
management have failed.AlthoughMorgan et al.5 have shown that
postoperative percutaneous transhepatic islet autotransplantation
after total pancreatectomy for chronic pancreatitis is safe and
more cost-effective than intraoperative infusion, all threemethods
of accessing the portal circulation should remain in the armamen-
tarium of centres performing total pancreatectomy and islet
autotransplantation for chronic pancreatitis.
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